Cite
HARVARD Citation
Kocoglu, M. et al. (n.d.). 47P Phase I study to assess the safety and efficacy of P-BCMA-ALLO1: A fully allogeneic CAR-T therapy, in patients with relapsed/refractory multiple myeloma (RRMM). Immuno-oncology technology. p. . [Online].